109617 ⎘
dsDNA viruses; Details; Adenoviridae Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
ACTIVATION OF RESIDENT MEMORY T CELLS FOR CANCER IMMUNOTHERAPY
#2ONCOLYTIC ADENOVIRAL VECTOR AND METHODS OF USE
#3Enhanced adoptive cell therapy
#4METHODS OF TREATING BLADDER CANCER
#5IMMUNE-CLOAKING ANTITUMOR ADENOVIRUS
#6TUMOR-SELECTIVE E1A AND E1B MUTANTS
#7METHODS OF TREATING SOLID OR LYMPHATIC TUMORS BY COMBINATION THERAPY
#8COMPOSITIONS AND METHODS FOR RETINAL NEURON GENERATION
#9REPROGRAMMED FUNCTIONAL FRAGMENT OF RECOMBINANT ONCOLYTIC VIRUS, COMBINATION, AND APPLICATION THEREOF
#10MUTANT E1A ANTAGONIZING UBIQUITINATION-MEDIATED DEGRADATION AND ITS USE IN THE PREPARATION OF POTENTIATED ONCOLYTIC ADENOVIRUSES AND IMMUNE POTENTIATORS
#11VIRUS ENCODING TRANSGENES TO COMPLEMENT CELLULAR THERAPY
#12ADENOVIRUS CONSTRUCTS AND METHODS OF USE
#13Recombinant Viral Genomes and Related Compositions and Methods
#14ANTICANCER COMPOSITION COMPRISING RECOMBINANT ADENOVIRUS EXPRESSING DEGRADATION FACTOR FOR EXTRACELLULAR MATRIX
#15METHOD FOR TREATING TUMOR WITH COMBINATION OF EXOGENOUS ANTIGEN AND THERAPEUTIC AGENT
#16SELECTIVE STIMULATION OF T CELLS IN SOLID TUMORS USING ONCOLYTIC VIRAL DELIVERY OF ORTHOGONAL IL-2
#17IMMUNOEVASIVE ANTI-TUMOR ADENOVIRUS
#18Therapeutic pharmaceutical composition for bone and soft tissue tumors
#19GROUP B ADENOVIRUS ENCODING AN ANTI-TCR-COMPLEX ANTIBODY OR FRAGMENT
#20ADENOVIRUS FOR TREATMENT OF CANCER
#21CHIMERIC BROAD-SPECTRUM ONCOLYTIC ADENOVIRUS WITH MULTIPLE MECHANISMS SYNERGIZING WITH AND ENHANCING EFFICACY OF IMMUNOTHERAPY, AND APPLICATION THEREOF IN TUMOR TREATMENT
#22Oncolytic Virus and Methods of Use
#23An oncolytic virus vector coding for variant interleukin-2 (vIL-2) polypeptide
#24RECOMBINANT VIRUSES, SURFACE-ENGINEERED DELIVERY SYSTEMS AND RELATED METHODS
#25Tumor-selective E1a and E1b mutants
#26RECOMBINANT ADENOVIRUS GENOME HAVING A SYNTHETIC TRANSCRIPTIONAL UNIT AND TWO STEP TRANSCRIPTIONAL REGULATION AND AMPLIFICATION
#27Methods of treating solid or lymphatic tumors by combination therapy
#28THERAPEUTIC AGENTS COMPRISING ONCOLYTIC VACCINIA VIRUSES AND NK CELLS, AND USES THEREOF FOR DRUGS FOR TREATMENT OF TUMORS AND/OR CANCERS
#29Methods of treating bladder cancer
#30METHODS OF TREATING BLADDER CANCER
#31Fast and Accurate Three-Plasmid Oncolytic Adenovirus Recombinant Packaging System AD5MIXPLUS and Application Thereof
#32VECTORIZED ANTIBODIES AND USES THEREOF
#33ONCOLYTIC ADENOVIRUS COMPOSITIONS
#34PH-sensitive and bioreducible polymer-virus complex for cancer treatment
#35DOSING REGIME AND FORMULATIONS FOR TYPE B ADENOVIRUSES
#36COMPOSITION COMPRISING NC886 FOR IMPROVING ONCOLYTIC VIRUS ACTIVITY OR PRODUCTION
#37Oncolytic virus expressing PD-1 binding protein and application of oncolytic virus
#38NOVEL AAV8 MUTANT CAPSIDS AND COMPOSITIONS CONTAINING SAME
#39Compositions and methods for treating type 1 and type 2 diabetes and related disorders
#40Tumor-selective E1A and E1B mutants
#41Replication-enhanced oncolytic adenoviruses
#42Methods of treating bladder cancer with an oncolytic virus
#43Activation of resident memory T cells for cancer immunotherapy
#44Enhanced adoptive cell therapy
#45TROPISM MODIFIED CANCER TERMINATOR VIRUS (AD.5/3 CTV;AD.5/3-CTV-M7)
#46Isolated recombinant oncolytic adenoviruses, pharmaceutical compositions, and uses thereof for drugs for treatment of tumors and/or cancers
#47Non-immunogenic protein nanoparticles with cancer targeting activity using albumin-binding peptide
#48Tissue Targeted Antigenic Activation of the Immune Response to Treat Cancers
#49Method for removing anti-AAV antibodies from a blood-derived composition
#50ANTICANCER COMPOSITION COMPRISING RECOMBINANT ADENOVIRUS EXPRESSING DEGRADATION FACTOR FOR EXTRACELLULAR MATRIX
#51Therapeutic agents and uses thereof for drugs for treatment of tumors and/or cancers
#52Tropism modified cancer terminator virus (Ad.5/3 CTV;Ad.5/3-CTV-M7)
#53ONCOLYTIC ADENOVIRUSES FOR CANCER TREATMENT
#54Tumor-selective E1a and E1b mutants
#55AAV8 mutant capsids and compositions containing same
#56Group B adenovirus encoding an anti-TCR-complex antibody or fragment
#57METHODS AND COMPOSITIONS FOR ATTENUATING GENE EXPRESSION MODULATING ANTI-VIRAL TRANSFER VECTOR IMMUNE RESPONSES
#58Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor
#59Virus encoding an anti-TCR-complex antibody or fragment
#60Methods and compositions for modulating AAV infection
#61Activation of resident memory T cells for cancer immunotherapy
#62Tissue Targeted Antigenic Activation of the Immune Response to Treat Cancers
#63Multitargeting onocolytic adenovirus, methods of use, and methods of making
#64LncRNA and oncolytic adenovirus, and application thereof
#65METHODS FOR TREATING TISSUE DAMAGE ASSOCIATED WITH ISCHEMIA WITH APOLIPOPROTEIN D
#66Regeneration of Inner Ear Cells
#67E1-MINUS ADENOVIRUSES AND USE THEREOF
#68AAV vectors with expanded packaging capacity
#69Enhanced adoptive cell therapy
#70Ph-sensitive and bioreducible polymer-virus complex for cancer treatment
#71Compositions and methods for treating type 1 and type 2 diabetes and related disorders
#72PPSA and Pspa polymer-virus complex and pharmaceutical compositions comprising the same
#73PHENOTYPIC REVERSION OF PANCREATIC CARCINOMA CELLS
#74Pharmaceutical composition comprising Nanog shRNA, and method of using Nanog shRNA to treat cancer
#75Oncolytic adenoviruses for cancer treatment
#76Tissue targeted antigenic activation of the immune response to treat cancers
#77Dosing regime and formulations for type B adenovirus
#78A PROCESS FOR THE PRODUCTION OF ADENOVIRUS
#79RECOMBINANT SEROTYPE 5 (Ad5) ADENOVIRAL VECTORS
#80METHODS AND COMPOSITIONS FOR ATTENUATING GENE EDITING ANTI-VIRAL TRANSFER VECTOR IMMUNE RESPONSES
#81METHODS AND COMPOSITIONS FOR ATTENUATING GENE THERAPY ANTI-VIRAL TRANSFER VECTOR IMMUNE RESPONSES
#82Use of adenoviruses and nucleic acids that code for said viruses
#83Methods and compositions for attenuating exon skipping anti-viral transfer vector immune responses
#84Methods and compositions for attenuating anti-viral transfer vector immune responses
#85Pharmaceutical composition comprising Nanog shRNA, and method of using Nanog shRNA to treat cancer
#86MiR-204 and miR-211 and uses thereof
#87TUMOR-SELECTIVE E1A AND E1B MUTANTS
#88Tropism modified cancer terminator virus (Ad.5/3 CTV;AD.5/3-CTV-M7)
#89AAV VECTORS EXPRESSING SEC10 FOR TREATING KIDNEY DAMAGE
#90Oncolytic adenovirus compositions
#91Methods for treating tissue damage associated with ischemia with apolipoprotein D
#92Tissue targeted antigenic activation of the immune response to treat cancers
#93METHOD AND COMPOSITION FOR TREATING SPASTICITY
#94Recombinant adenovirus with increased safety and anticancer activities, and use thereof
#95PHENOTYPIC REVERSION OF PANCREATIC CARCINOMA CELLS
#96Oncolytic adenovirus armed with therapeutic genes
#97Composition of viral vectors in lecithin liposomes, preparation method and treatment methods
#98ONCOLYTIC VIRUS ENCODING PD-1 BINDING AGENTS AND USES OF THE SAME
#99Enhanced adoptive cell therapy
#100Oncolytic Adenoviruses for Cancer Treatment
#101Chimeric adenoviruses for use in cancer treatment
#102Chimeric adenoviruses for use in cancer treatment
#103Chimeric adenoviruses for use in cancer treatment
#104Phenotypic reversion of pancreatic carcinoma cells
#105CLINICAL APPLICATIONS OF A RECOMBINANT HUMAN ENDOSTATIN ADENOVIRUS (E10A) INJECTION
#106AAV Vectors Expressing SEC10 for Treating Kidney Damage
#107Chimeric adenoviruses for use in cancer treatment
#108Viruses for the treatment of cellular proliferative disorders
#109E1-MINUS ADENOVIRUSES AND USE THEREOF
#110Tumor selective E1a and E1b mutants
#111NOVEL USE OF ADENOVIRUSES AND NUCLEIC ACIDS THAT CODE FOR SAID VIRUSES
#112Tissue targeted antigenic activation of the immune response to treat cancers
#113NOVEL USE OF ADENOVIRUSES AND NUCLEIC ACIDS THAT CODE FOR SAID VIRUSES
#114Viruses for the treatment of cellular proliferative disorders
#115Oncolytic Adenoviruses for Cancer Treatment
#116PHENOTYPIC REVERSION OF PANCREATIC CARCINOMA CELLS
#117E1-MINUS ADENOVIRUSES AND USE THEREOF
#118Chimeric adenoviruses for use in cancer treatment
#119IMMOBILISATION AND STABILISATION OF VIRUS
#120ANTIVIRAL ACTIVITY OF CIDOFOVIR AGAINST ONCOLYTIC VIRUSES
#121Oncolytic adenovirus armed with therapeutic genes
#122Phenotypic reversion of pancreatic carcinoma cells
#123Viruses for the treatment of cellular proliferative disorders
#124Viruses for the treatment of cellular proliferative disorders
#125Viruses for the treatment of cellular proliferative disorders
#126Methods and Compositions for Viral Enhancement of Cell Killing
#127Novel use of adenoviruses and nucleic acids that code for said viruses
#128Viruses for the treatment of cellular proliferative disorders
#129Oncolytic adenovirus armed with therapeutic genes
#130Phenotypic reversion of pancreatic carcinoma cells
#131Chimeric adenoviruses for use in cancer treatment
#132Immobilisation and stabilisation of virus
#133Methods and compositions for viral enhancement of cell killing
#134Method for production of oncolytic adenoviruses
#135TAA/ecdCD40L oncolytic virus